PsoriasisBiologicalDrug
What this study is
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
What's being tested
- Brodalumab
Intervention · BIOLOGICAL
Brodalumab
- Comparator Drug (non-biologic IL-17 inhibitors)
Intervention · DRUG
Comparator subjects treated with non-biologic IL-17 inhibitors
Study details
- Official title
- Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
- Sponsor
- Bausch Health Americas, Inc.
- Conditions
- Psoriasis
- Enrolling
- 3,500 people
- Starts
- 2017-07-25
- Est. completion
- 2031-11
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 99 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Diagnosis and main criteria for inclusion: a subject must have moderate to severe psoriasis diagnosed by a dermatologist
- Must be at least 18 years of age or older
- Started on or switched to a systemic psoriasis treatment within the previous 12 months. FDA-approved biologic treatments and select non-biologic treatments (eg, methotrexate, cyclosporine, or apremilast only) are permitted.
You can't join if
- The subject is unable or unwilling to provide informed consent to participate in the registry.
- The subject is participating or planning to participate in a clinical trial with a non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).
- The subject is restarting the eligible medication less than 12 months since receiving the last dose.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openRegistry
Bridgewater, New Jersey, United States
Study team
Sponsor
Bausch Health Americas, Inc.
Study ID V01-BROA-402
Study director
Varsha Bhatt
Bausch Health
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.